RxDoctor Payments DataLook up a doctor →

Michael Krease, DO

Gastroenterology · Louisville, KYNPI 1003255365

Payments from drug & device makers

$694,431in general payments, 2019–2025

Across 1,370 payments — averaging $506.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$208K
  • Genentech, Inc.$101K
  • AbbVie$93K
  • F. Hoffmann-la Roche AG$92K
  • Teva Pharmaceuticals USA, Inc.$89K
  • Regeneron Healthcare Solutions, Inc.$61K
  • plus $49K from 39 others

What the payments were for

  • Consulting fees$16,1595%
  • Speaking & faculty fees$271,81984%
  • Travel & lodging$11,6344%
  • Food & beverage$21,8487%
  • Education$3080%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$694,431 in reported general payments places this provider in the 95th percentile of 207 gastroenterology providers in Kentucky.

See all gastroenterology providers in Kentucky

Medicare billing

Part B allowed, 2024
$221,618
Medicare patients
531
Services billed
5,265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab19$515,570
SucraidSacrosidase17$231,549
Skyrizi On-BodyRisankizumab-Rzaa12$227,895
Humira(Cf) PenAdalimumab30$201,528
Dupixent PenDupilumab12$89,745
XifaxanRifaximin14$43,238
CreonLipase/Protease/Amylase19$37,313
DipentumOlsalazine Sodium14$23,648
LinzessLinaclotide23$20,191
Mesalamine18$15,634
Mesalamine ErMesalamine21$7,442
Dexlansoprazole DrDexlansoprazole14$5,266
Mesalamine DrMesalamine20$3,362
Omeprazole253$3,052
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates42$2,808

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$2,717$515,57019 claims
QOL Medical, LLCSucraid$303$231,54917 claims
AbbVieCreon, Linzess$93,393$57,50442 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,635$43,23814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 207 gastroenterology providers in Kentucky.

Other gastroenterology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →